:

RAMP RAISES $750M AT $44B VALUATION

AI DESK■ 1 MIN READ
THU, JUN 4, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Ramp, a corporate spending management platform, secured $750 million in funding at a $44 billion valuation. The round was led by Iconiq, Singapore's GIC, and the Ontario Teachers' Pension Plan (OTPP).

The funding brings Ramp's total capital raised to $3 billion, reflecting strong investor confidence in the spend management sector. The platform helps companies manage corporate expenses, vendor payments, and employee spending through a unified system. The latest round includes participation from major institutional investors, signaling growing interest in enterprise financial infrastructure. Ramp competes in a market that has seen significant consolidation and growth as businesses increasingly digitize their financial operations. The $44 billion valuation places Ramp among the most valuable venture-backed companies in the fintech sector, despite macroeconomic headwinds affecting startup funding. The platform has expanded its product offerings and customer base since its 2019 launch, targeting mid-market and enterprise customers seeking streamlined expense management solutions.

■ SOURCES

► Techmeme

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE STARTUPS DESK

DeepSeek's annualized revenue run rate has doubled to $1 billion in recent months, up from less than $500 million. The Chinese AI company aims to close a $7.5 billion fundraise by late October.

JUST NOW— AI Desk

Modal Labs and Baseten, two platforms enabling businesses to run AI models, are in advanced funding talks that would significantly boost their valuations. The rounds reflect growing investor appetite for AI infrastructure services.

11H AGO— AI Desk

Ema, an AI agent platform automating corporate processes in HR, IT, and finance, secured $77 million in Series B funding led by Creaegis. The round brings the startup's total funding to $140 million.

13H AGO— AI Desk

Enveda Therapeutics raised $311 million in funding, bringing the AI biotech company's valuation to $2 billion. The capital will accelerate clinical trials for drugs derived from natural compounds.

14H AGO— AI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.